Encapsidation of cellular-or plasmid-derived DNA sequences during recombinant adeno-associated virus (rAAV) production has been well documented. However, most of the published data were generated from rAAV vectors manufactured by the plasmid transient transfection method. We previously reported a novel, scalable method for rAAV manufacturing based on a recombinant herpes simplex virus (rHSV) complementation system. In this report, we evaluated clearance of DNA impurities during rAAV purification, by determining the quantity of residual herpes simplex virus and cellular DNA at each process step. A single Benzonase treatment during the upstream process effectively reduced unprotected HSV and cellular DNA to o300 bp fragments, and subsequent chromatography steps completely removed these small DNA fragments. Further analysis showed that trace amounts of residual, DNase-resistant HSV and cellular DNA were present at static concentrations during subsequent purification steps, and the residual HSV DNA sequences were single stranded, ranging from 0.8 to 4.2 kb. After transduction of human embryonic kidney 293 cells with purified rAAV, the residual HSV DNA fragments were neither transcribed nor translated into HSV proteins. In summary, this manufacturing process for rAAV production was effective in removing DNA and protein contaminants and achieving a highly purified product, suitable for human clinical application.
INTRODUCTION
Wild-type adeno-associated virus (AAV) is a non-pathogenic member of the Parvoviridae family with a 4.7 kb single-stranded DNA genome that consists of only two open reading frames, rep and cap. 1 Recombinant AAV (rAAV) vectors, in which the rep and cap genes are replaced with a therapeutic transgene expression cassette, have been widely evaluated for gene-delivery applications in vivo, with several serotypes under evaluation in a human clinical setting. [2] [3] [4] [5] Robust, long-term gene expression, transduction of a broad spectrum of target tissues, and an excellent safety profile are some of the attributes that make AAV-based vectors highly attractive as gene-transfer vehicles.
rAAV manufacturing is non-trivial; viral helper functions are provided in trans by either helper viruses or plasmids, or a combination thereof, to permit viral replication and packaging. 6 Several recent reports on rAAV preparations produced by either the plasmid transient transfection method or stable producer cells have documented that DNA sequences other than the therapeutic transgene expression cassette are encapsidated into rAAV particles. [7] [8] [9] Non-transgene DNA sequences, including AAV2 rep and antibiotic resistance gene sequences (Amp r and/or Kan r ), were reported to be present at levels up to 6.3% of the total rAAV vector genomes (vg). 7, 8 Transcription of encapsidated rep and cap sequences in rAAV preparations has also been reported, and was suggested to have a potential impact on vector performance in vivo. 7 Evaluation of an rAAV2-hFIX vector made by plasmid transient transfection and used in a clinical trial also found that non-transgene DNA sequences were packaged, but no transcription of AAV2 cap or other DNA sequences was detected. 9 Furthermore, characterization of rAAV-like particles produced in human embryonic kidney (HEK) 293 cells by an adenovirus-assisted method has revealed that small (100 bp) to moderately sized (700 bp) DNA sequences can be encapsidated in the absence of all AAV transand cis-acting elements (rep and inverted-terminal repeat (ITR)). 10 Taken together, these findings suggest that careful evaluation of process-related DNA contaminants is critical to the understanding of the safety profile of rAAV generated by both established (for example transient transfection) and emerging (for example those based on recombinant herpes simplex virus (rHSV) and baculovirus helpers) manufacturing methods.
Recently, we have advanced an rHSV-based method for rAAV production and purification to the point of clinical relevance. 11, 12 This method uses two ICP27-deletion mutants of HSV-1, bearing either the AAV rep and cap genes, or the transgene expression cassette with flanking AAV ITR sequences, to simultaneously infect producer cells in either adherent or suspension cell culture. Using this method, we have generated large-scale rAAV vector batches (in excess of 10 15 vg of rAAV per batch) for preclinical safety studies and carefully characterized the final purified material. 12 In this study, we substantially expanded the characterization of the residual DNA contaminants during purification of rAAV produced in suspension baby hamster kidney (BHK) cells. We found that a small amount of residual HSV and BHK cellular DNA remained after an initial DNase treatment and persisted at static concentrations during subsequent steps in the purification process, suggesting that residual HSV and cellular DNA are likely encapsidated. We also determined the size distribution of the residual HSV DNA, showed that the residual HSV DNA sequences did not generate mRNA transcripts or express proteins, and characterized the density of HSV-DNA-containing rAAV particles by CsCl gradient ultracentrifugation. To our knowledge, this is the first report of a comprehensive characterization of residual DNA contaminants in clinically relevant rAAV vectors produced by a method other than the plasmid transient transfection or a stable producer cell line method.
RESULTS
HSV DNA sequences were randomly packaged during rAAV production by rHSV helpers Previous studies have reported encapsidation of non-transgene DNA sequences during production of rAAV by plasmid transient transfection and stable producer cell line methods. 7, 8 To determine whether such undesirable packaging of non-transgene DNA sequences might be reduced during rHSV-based rAAV production, two lots of rAAV1 vector expressing the human a-1 antitrypsin (rAAV1-CB-hAAT) generated and purified as described in Materials and Methods were subjected to an extensive nuclease treatment to remove any nonencapsidated nucleic acid impurities, and assessed for the presence of particles containing HSV DNA by a real-time quantitative PCR (qPCR) assay targeted to the HSV UL36 gene sequence. The HSV UL36 sequence was found to be packaged at 0.0076-0.0094% of the total rAAV vg, accounting for 6.4-7.8 ng of total HSV DNA per 1Â10 12 rAAV vg ( Table 1) . As a control, wild-type HSV (wtHSV) DNA spiked into rAAV1-CB-hAAT made by a plasmid transient transfection method, which is free of HSV DNA sequences, was completely removed by the process of nuclease treatment, indicating that nuclease treatment was effective at removing any unprotected HSV DNA at a concentration similar to that detected in purified rAAV1-CB-hAAT made by herpes helper viruses (Table 1) . There was no significant difference in the amount of HSV-1 UL36 sequences detected in rAAV1-CB-hAAT preparations with and without nuclease treatment ( Table 1 ), suggesting that all HSV-1 UL36 sequences present in purified rAAV1-CB-hAAT virus stocks were packaged and protected from nuclease.
The HSV genome is approximately 152 kb and encodes 480 genes, which vary in size from approximately 260-9400 bp. To test whether there was any preferential encapsidation of specific HSV sequences, primer-probe sets corresponding to four independent amplicons mapped to the HSV UL26.5, UL29, UL33, and UL36 genes were used to quantify residual HSV DNA by qPCR in two lots of purified rAAV1-CB-hAAT virus stocks. All four HSV DNA sequences were present in similar amounts, with copy numbers ranging between 0.01 and 0.026% of the total rAAV vg. Additional primer-probe sets mapping to the HSV UL5, UL23, UL30, and UL52 genes were also used to quantify residual HSV DNA by qPCR in another lot of rAAV, and the residual HSV DNA copies were detected again at similar levels. The HSV UL23 (tk) gene was selected due to its insertional relevance (Figure 1) , and the amplicon mapped to UL23 resides o1 kb away from the transgene insertion site. Altogether, these data suggested that HSV DNA sequences were packaged randomly during rAAV production, and comprised of random fragments from across the entire HSV genome. The total amount of HSV DNA in the purified rAAV preparations tested was approximately 10-20 ng per 1Â10 12 rAAV vg.
Residual HSV DNA fragments between 0.8 and 4.2 kb persisted throughout the rAAV purification process Production of rAAV1-CB-hAAT in suspension BHK cells requires co-infection with rHSV-rep2/cap1 and rHSV-CB-hAAT helper viruses (Figure 1 ), lysis of infected producer cells to liberate rAAV particles, incubation with Benzonase to digest unpackaged host and viral DNA, concentration and buffer exchange, and column chromatography operations. To evaluate the capability of each major process step to remove HSV and BHK cellular DNA contaminants, total DNA was extracted from samples removed throughout the process. The rAAV vg and residual HSV and BHK cellular DNA in the total DNA extracted were determined by qPCR. As shown in Figure 2 , the amount of HSV DNA and BHK cellular DNA per 1Â10 12 rAAV vg detected in the unprocessed bulk harvest material was approximately 3000 ng and 10 000 ng, respectively. These were reduced by about 300-and 1000-fold, respectively, during the initial cell lysis, Benzonase treatment and clarification steps. The amount of HSV and BHK cellular DNA detected at each subsequent purification step remained constant at approximately 10 ng per 1Â10 12 rAAV vg for HSV DNA, and 0.2 ng per 1Â10 12 rAAV vg for BHK cellular DNA (Figure 2) .
We next examined the size distribution of residual HSV DNA from each major step in the purification process. Although Southern blot analysis is a standard method for determining the size distribution of DNA, the high G/C content and the internal repeat sequences present in both HSV and rAAV1-CB-hAAT genomes were found to result in non-specific hybridization when probing for residual HSV DNA using probes derived from the whole HSV-1 genome, most likely due to the excess of rAAV1-CB-hAAT vg DNA. To circumvent this problem, without sacrificing assay sensitivity, two large HSV DNA fragments (30-45 kbp) isolated from cosmids containing wtHSV DNA sequences 13 were pooled and used to prepare the probe. The combined sequences of these two HSV DNA fragments consisted primarily of the unique long (U L ) segment of the HSV genome, but lacking the internal and terminal repeated sequences. As shown in Figure 3 , a single Benzonase treatment reduced the majority of cellular and HSV DNA to o300 bp (Figure 3a, Lane 3) . After the first-column chromatography step, these small DNA fragments were no longer detectable in an agarose gel; only the double-and single-stranded rAAV1-CB-hAAT vg DNA (3.85 and 1.2 kb, respectively) were seen ( Figure 3a , Lanes 6 and 7). Southern blot analysis also confirmed that HSV DNA fragments smaller than 300 bp were effectively removed after the first-column chromatography step (Figure 3b , Lanes 6 and 7). However, residual HSV DNA migrated as a smear corresponding to 0.5-1.6 kb of dsDNA was detected by Southern blot analysis, and persisted at static levels throughout the purification process (Figure 3b, Lanes 3-7) . The rAAV1-CB-hAAT made by plasmid transient transfection (for example free of HSV DNA sequences) was included as a Southern blot negative control (Figure 3b , Lane 9). In addition, pCB-AT0, the same plasmid used for rAAV1-CB-hAAT production by plasmid transfection method, was also included as a control after digestion with PciI/PvuI (Figure 3a , Lane 8) . No nonspecific hybridization was observed from the rAAV1-CB-hAAT made by plasmid transient transfection even when a two-fold excess of DNA was loaded relative to in-process samples (Figure 3b , Lane 9). However, weak non-specific hybridizations to the plasmid backbone sequences of pCB-AT0 (the 2.2 kb plasmid backbone sequence and the 4 kb DNA fragment containing both vg and partial plasmid backbone sequences) were observed ( Figure 3b , Lane 8). The limit of detection of the Southern blot assay for AluI-digested wtHSV DNA was determined to be 1 ng (Figure 3b , Lanes 11-13).
To examine the nature of residual HSV DNA, total DNA extracted from purified rAAV1-CB-hAAT made by HSV helper virus, together with the positive control HSV DNA (AluI digests), either heat denatured to separate dsDNA into ssDNA immediately before loading or without any treatment, was separated on an agarose gel, transferred to a nylon membrane under neutral conditions, and hybridized to a probe made from HSV DNA. As shown in Figure 3 Packaging of AAV rep sequences occurred at similar frequencies to that of HSV DNA and was independent of promoter We quantified the level of packaged HSV DNA and AAV rep gene sequences in five lots of rAAV vector produced by the rHSV-based method. Three of these five lots were rAAV1-CB-hAAT, in which residual BHK cellular DNA was also quantified. The other two lots were rAAV2-p5-GFP (made using an rHSV-rep2/cap2 helper virus containing the native p5 promoter of the AAV rep gene and an rHSV-GFP helper virus containing a green fluorescent protein expression cassette) and rAAV2-mouse mammary tumor virus (MMTV)-GFP (made with an rHSV-rep2/cap2 helper virus in which the AAV native p5 promoter was replaced with the MMTV long-terminal promoter from pDG and an rHSV-GFP helper virus) ( Figure 1 ). The amount of residual BHK cellular DNA determined in all three lots of rAAV1-CBhAAT was between 0.1 and 0.2 ng per 1Â10 12 rAAV vg. Although residual HSV DNA determined by HSV UL36 qPCR (0.008-0.012% of the total rAAV vg) was similar in all five lots of rAAV, the level of encapsidated AAV rep sequences in rAAV2-MMTV-GFP was also similar to that of the other four lots of rAAV (0.007-0.014% of total rAAV vg) ( Table 2 ). These data suggest that encapsidation of non-transgene DNA sequences during rAAV production is non-specific and not related to the presence of a rep-binding element.
No protein expression or transcripts of residual HSV DNA were detected in rAAV-transduced cells To investigate the transcriptional and protein expression potential of residual HSV DNA in rAAV vector preparations, we evaluated the expression of three HSV proteins (ICP0, ICP8, and ICP35) in HEK 293 cells transduced with purified rAAV1-CB-hAAT by immunofluorescent assays. The HSV proteins were selected based on their distinct kinetic group associations in the immediate-early, early, and late stages of the HSV replication cycle, respectively. 14 Strong HSV protein expression was detected for all three HSV gene products in cells infected with 20 PFU of wtHSV per chamber, in the presence or Figure 2 Residual HSV and BHK cellular DNA concentrations at various steps through the rAAV1-CB-hAAT manufacturing process. Total DNA was extracted with phenol-chloroform from aliquots made after each major process step and the concentrations of rAAV vector genome, HSV DNA, and BHK cellular DNA were quantified by qPCR as described in Materials and Methods. The amount of HSV DNA (') was expressed as ng per 1Â10 12 vg of rAAV, assuming that each copy of HSV UL36 sequence quantified based on a plasmid standard represented one copy of the HSV 152 kb genome. The BHK cellular DNA (&) was also expressed as ng per 1Â10 12 vg of rAAV. The standard used for BHK cellular DNA qPCR was the genomic DNA purified from BHK cells. Samples were obtained from unpurified bulk (pre-lysis), post-filter clarified cell lysate, post-tangential flow filtration (TFF pool), post-diafiltration (DF pool), material after anion exchange chromatography (Q peak), and material after affinity chromatography (AVB peak). The AVB peak pre-DNA extraction was included as a control for determining the DNA recovery during extraction. Error bars indicate the s.d. of triplicate qPCR reactions. absence of rAAV1-CB-hAAT (1Â10 5 vg per cell) (Figures 4b, c, g , h, k, and l), but there was no detectable expression of any of the three HSV proteins in cells mock infected or transduced with rAAV1-CBhAAT (Figures 4a, d , f, i, j, and m). All cells transduced with rAAV1-CBhAAT expressed hAAT, although only weak staining was observed because hAAT is a secreted protein (Figures 4e and n) .
As detection of protein expression by immunofluorescent assays methods may be relatively insensitive, we further evaluated the transcriptional potential of residual HSV DNA using a reversetranscription qPCR (RT-qPCR) method on samples from cells transduced with rAAV1-CB-hAAT. Primer-probe sets targeting the 5¢ end of five different HSV genes (UL26.5, UL33, UL29, UL35, and UL36) were used to quantitatively evaluate potential transcription in HEK 293 cells transduced with two lots of HSV-produced rAAV1-CBhAAT and one lot of plasmid transfection-produced rAAV1-CB-hAAT.
Each vector lot exhibited a dose-dependent increase in hAAT mRNA expression when HEK 293 cells were transduced, but no transcription of any of the five HSV genes was detected at any multiplicity of infection examined (Table 3) . HEK 293 cells infected with wtHSV (KOS strain, multiplicity of infection 0.01) served as a positive control, and all five HSV gene transcripts were readily detected ( Table 3 ). The limit of detection of the RT-qPCR assays for each HSV gene expression, measured by the lowest copy number of HSV CS32 cosmid DNA spiked into 100 ng of total RNA isolated from infected HEK 293 cells, was 140-200 copies per 100 ng input RNA, corresponding to one copy per 50-70 cells. Taken together, these data indicated that the trace amounts of residual HSV DNA present in purified rAAV preparations made by the HSV co-infection method do not result in detectable HSV RNA transcription or HSV protein expression. Figure 4 Immunofluorescence assay for HSV protein expression in rAAV1-CB-hAAT transduced cells. Vero cells were mock infected (Mock), infected with wild-type HSV at 20 PFU per chamber (wtHSV), infected with wild-type HSV at 20 PFU per chamber and rAAV1-CB-hAAT at 1Â10 5 vg per cell (wtHSV + rAAV), or infected with rAAV1-CB-hAAT at 1Â10 5 vg per cell (rAAV1-AAT). Cells were cultured for 48 h, fixed and reacted with monoclonal antibody to HSV ICP0 (a, b, c, d), ICP8 (f, g, h, i), ICP35 (j, k, l, m), or rabbit antiserum to human a-1 antitrypsin (AAT) (e, n), followed by FITC-labeled anti-mouse IgG or Texas Red-labeled anti-rabbit IgG. Images were collected using a Zeiss fluorescence microscope equipped with a digital camera.
No HSV proteins were detected in HSV DNA-containing AAV particles partially co-purified with full rAAV particles during CsCl density gradient ultracentrifugation An aliquot of purified rAAV1-CB-hAAT (2Â10 13 vg) made by rHSV helper viruses was subjected to CsCl gradient ultracentrifugation and fractionation, followed by qPCR analysis of HSV DNA and rAAV vector DNA and ELISA analysis of AAV1 capsid protein, as described in Materials and Methods. These analyses showed that empty AAV particles ( Figure 5 , fractions 24-29), corresponding to approximately half of the total AAV particles (48%), could be completely separated from the full (for example vg-containing) AAV particles ( Figure 5 , fractions 8-17), whereas HSV-DNA-containing particles were separated into two overlapping peaks. One of these two peaks ( Figure 5 , Peak II) appeared to be completely within the full AAV particle peak, but the HSV-DNA-containing particle Peak I (fractions 6-8) exhibited a density higher than that of rAAV1-CB-hAAT vg-containing particle peak. Silver staining of purified rAAV subjected to SDS-PAGE resulted in only the AAV VP1, VP2, and VP3 proteins visible in the HSV-DNAcontaining peaks (Peaks I and II), empty particle peak, and the purified rAAV1-CB-hAAT before CsCl density gradient ultracentrifugation (Figure 6a ). ECL western blot analysis for residual HSV proteins further indicated that there was no HSV proteins detected not only in empty particles and the purified rAAV1-CB-hAAT, but also in both HSV-DNA-containing particle peaks (Peaks I and II) (Figure 6b ). This excluded the possibility that the residual HSV DNA detected in purified rAAV was from HSV capsids that could co-purify with rAAV.
DISCUSSION
A variety of methods have been used to produce rAAV vectors suitable for use in human clinical trials, including multiple plasmid transient transfection methods, 15 stable producer cell lines containing some or all components required for vector production, 16 baculovirus-based methods, 17 and rHSV-based methods. 18, 19 Non-transgene DNA sequences have been universally detected in purified rAAV vector preparations to this point, regardless of the manufacturing method Figure 5 CsCl gradient analysis of rAAV1-CB-hAAT. rAAV1-CB-hAAT purified by column chromatography was subjected to CsCl gradient ultracentrifugation. Fractions (0.30 ml) collected from the bottom of the tube were subjected to analysis for rAAV capsid by AAV1 specific capsid ELISA (shaded, capsids per ml), rAAV vector genome (dash shaded, vg ml -1 ), and residual HSV DNA (open, ng ml -1 ) by qPCR. Dashed line represents the density of individual fractions. Peaks I and II are the two peaks that contained the most residual HSV DNA.
used. [7] [8] [9] Using an rHSV-based method to produce rAAV1-CB-hAAT vectors, we found that residual HSV DNA sequences were randomly packaged, and the average HSV DNA sequence copy numbers detected were approximately 0.012% of the total rAAV vg, corresponding to approximately 10 ng of total HSV DNA per 1Â10 12 vg of rAAV. This is at least 100-fold less than the level of residual plasmid DNA (1.2-6.3% of the total rAAV vg) reported by Chadeuf et al., 8 and, when expressed as ng of residual DNA per 1Â10 12 vg of rAAV, is comparable with the lowest amount of residual plasmid DNA reported by Hauck et al. 9 (10 ng vs 8.6 ng). The encapsidated residual HSV DNA sequences are most likely single-stranded DNA based on the observations from Southern blot analysis of DNA transferred under neutral conditions, although we could not completely exclude the possibility that part of the encapsidated HSV DNA are double stranded. The significantly stronger hybridization signals after heat denaturation of DNA samples suggested that part of the residual HSV DNA in the extracted DNA samples are double stranded, which was prevented from hybridization to probes without denaturing. The double-stranded HSV DNA could be formed from complementary encapsidated single-stranded HSV DNA molecules after DNA extraction. The mechanism of random encapsidation of single-stranded HSV DNA, which is unlikely to contain any elements that serve as signals for encapsidation into AAV particle, is yet to be defined. Residual cellular DNA is a parameter of particular interest for regulatory authorities and there is little published data available for residual host cell DNA in rAAV products. The average amount of residual BHK cellular DNA (approximately 0.15 ng per 1Â10 12 vg of rAAV) determined in three lots of rAAV1-CB-hAAT was 30-to 1000-fold less than that of reported residual HEK 293 cellular DNA in rAAV products purified with different methods. 9 Although assay methodology differences between laboratories could be a contributing factor for such a large difference of reported residual cellular DNA in rAAV products, it also suggested that the levels of encapsidated residual cellular DNA is production process dependent. Overall, these data suggested that the HSV complementation system appears to show a reduction in packaged, non-transgene DNA, including the cellular DNA sequences, relative to other production methods.
It has been reported that rAAV preparations produced using the pDG plasmid, in which the p5 promoter region of the AAV rep gene was replaced with an MMTV long-terminal promoter, are free of particles containing rep sequences. 7, 20 In contrast, the level of rep sequences determined in rAAV2-MMTV-GFP produced using an rHSV-MMTV-rep2/cap2 helper virus containing the MMTV promoter (0.014% of the total rAAV vg) was found similar to that determined in rAAV2-p5-GFP (0.012% of the total rAAV vg) and rAAV1-CB-hAAT (0.007 to 0.013% of the total rAAV vg) produced using an rHSV-rep2/capX helper virus containing the AAV native p5 promoter ( Table 2 ). The extremely low percentage of encapsidated HSV and rep DNA sequences in rAAV preparations produced by this rHSV-based production method may stem from the large rHSV genome size (152 kb), and is supported by observations that increasing the size of the production plasmid backbone with a plasmid transient transfection system can significantly reduce the levels of encapsidated, non-transgene DNA sequences. 9 The rHSV helper viruses used in our rAAV production system are replication defective because they lack the gene for HSV ICP27, an immediate-early gene product that is essential for HSV viral DNA replication and regulation of other early gene expression. 21, 22 Recently, a large Phase I/II clinical study (485 participants) was conducted, which explored the safety of a glycoprotein H gene deficient, replication competent HSV as a vaccine for genital herpes, and yielded an excellent safety profile. 23 Furthermore, the HSV-1 KOS strain from which all rHSV helper viruses were derived has been shown nontumorigenic in vivo. 24 Despite these recent findings, potential tumorigenic and/or immunogenic side effects of residual HSV DNA and/or the potential resulting proteins expressed are a potential concern. To this end, we assessed the size distribution and the transcription of residual HSV DNA.
We were unable to detect HSV gene transcription or protein expression from the residual HSV sequences detected in the purified , and Peak III (empty particles) from CsCl density gradient ultracentrifugation of AVB peak (see Figure 5 ).
rAAV1-CB-hAAT preparations. Five HSV genes, UL26.5, UL29, UL33, UL35, and UL36 were selected for in vitro transcription assessment through RT-qPCR; and three genes, a0 (ICP0), UL26.5 (ICP35), and UL29 (ICP8), were selected for protein expression assay by immunofluorescence. a0 (ICP0), UL29 (ICP8), and UL26.5 (ICP35) are immediate-early, early, and late genes, respectively, and represent all three kinetic groups of HSV genes. Expression of ICP0 and ICP8 do not require viral DNA replication. 14 More importantly, ICP8 is one of a few HSV proteins that provide helper functions for AAV replication. 25 Other genes (UL26.5, UL33, UL35) were selected because of their relatively small sizes (1044, 1782, and 377 bp, respectively), which might facilitate packaging in AAV as intact genes relative to other, larger genes. It was perhaps unsurprising that neither HSV protein expression nor RNA transcripts were detected, given the total amount of residual HSV DNA in purified rAAV preparations was extremely low. In addition, HSV genes are transcribed and expressed in a highly regulated cascade manner, and transcription of most HSV genes requires earlier viral DNA replication and protein synthesis, which is unlikely to be supported by purified rAAV preparations. 14 Historically, density gradient ultracentrifugation has been a useful tool for separating and studying empty viral particles and/or lighter, particle-associated impurities from the heavier rAAV particles containing vector DNA. 26, 27 CsCl gradient fractions containing HSV DNA appeared to form two bands, one which was heavier (densities from 1.40-1.43 g cm -3 ) than the other that was completely overlapped with the AAV vg-containing particles (densities from 1.36-1.40 g cm -3 ). Analysis of the final purified rAAV vector (Figure 6b, Lane 2) , and the fractions of CsCl gradient of rAAV vector (Figure 6b , Lanes 3-5) by ECL western blot with a polyclonal antibody to HSV proteins showed no detectable HSV proteins (except for weak non-specific reaction of the antibody to AAV VP3), suggesting that the residual HSV DNA detected in the rAAV product is not encapsidated in HSV particles (Figure 6b ). On the basis of the size distribution of the residual HSV DNA determined by Southern blot analysis, it is reasonable to attribute the heavier HSV-DNA-containing particles to those that encapsidated residual HSV DNA fragments larger than the transgene cassette size (3.86 kb). The data from density gradient analysis of AAV vector are thus consistent with the conclusion that the residual encapsidated HSV DNA sequences are single stranded.
In conclusion, we have shown robust clearance of contaminating HSV DNA, BHK cellular DNA, and HSV proteins during the purification of rAAV1-CB-hAAT produced by an rHSV complementation method. The trace amount of residual HSV DNA that persisted through the process appears to be randomly generated fragments that are packaged into AAV capsids and do not result in either detectable RNA transcription or protein expression after transduction of cells by rAAV vectors.
MATERIALS AND METHODS

rHSV-1 vector construction and production
The rHSV-rep2/capX that contains the native AAV p5 promoter (with X representing any AAV capsid serotype) and rHSV-GOI (with GOI representing any gene of interest) viruses ( Figure 1) were constructed by homologous recombination of an AAV rep2/capX or GOI gene cassette into the tk locus of the ICP27-deleted rHSV-1 vector (d27.1) through recombination plasmid pHSV106-rep2/capX or pHSV106-GOI, respectively. 11 rHSV-MMTV-rep2/ cap2 (Figure 1) , in which the native AAV p5 promoter was replaced with an MMTV long-terminal promoter, was constructed through pHSV106-MMTVrep2/cap2, a recombination plasmid derived from pHSV106-rep2/cap2 by replacing the p5-rep2/cap2 sequence with the MMTV-rep2/cap2 sequence released from pDG by Xba I digestion. The rHSV vectors were propagated on V27 cells as previously described. 11 rAAV production, purification, in-process sampling, and total DNA extraction
The rAAV was produced and purified as previously described. 12 Briefly, suspension baby hamster kidney cells were co-infected with rHSV-rep2/cap1 and rHSV-AAV-hAAT, and the resulting rAAV1-CB-hAAT vector was liberated from cells by addition of Triton X-100 (1% (v/v)), Benzonase (25 U ml -1 ), and MgCl 2 (2 mM). After 2-4 h incubation at 37 1C with continued rocking, the resulting crude lysate was clarified by depth filtration (1.2 mm) and absolute filtration (0.8/0.45 mm), followed by flat sheet tangential flow filtration (TFF)-mediated concentration and buffer exchange as previously described. 12 The vector was recovered from the resulting process intermediate by a two-column chromatography procedure consisting of an anion exchange capture step and affinity chromatography polishing step. Finally, the post-chromatography intermediate was concentrated up to 2-fold and then 10-fold buffer exchanged into Lactated Ringer's Solution using a Sartocon Slice 200 cm 2 , 100 kDa MWCO flat sheet holder, and associated membrane (Sartorius-Stedim Biotech, Inc., Aubagne Cedex, France).
Aliquots made after each major in-process step were subjected to total DNA extraction. A total of six samplings were made: (1) pre-lysis harvest, (2) clarified cell lysate, (3) post-TFF retentate (TFF Pool), (4) post-DF retentate (DF Pool), (5) post-anion exchange column pool (Q Peak), and (6) post-AVB affinity column pool (AVB Peak). All samples were first treated with Proteinase K (final concentration of 0.2 mg ml -1 , 1 h at 55 1C) before DNA extraction with phenol/chloroform. Extracted DNA was resuspended in 1ÂTE buffer (10 mM Tris-HCl, 1 mM EDTA, pH8.0) and the DNA was quantified by spectrophotometry. DNA recovery during the extraction step was calculated based on qPCR quantification of rAAV and HSV DNA before and after DNA extraction.
Quantification of AAV vgs, residual BHK cellular DNA, and residual HSV DNA, by qPCR
The concentrations of rAAV vg in crude and purified rAAV vector stocks were determined by qPCR as previously described. 11 The rAAV vg in total DNA extracted from in-process samples and purified rAAV vector was determined using the same method, but without pretreatment with DNase I and Proteinase K.
The concentration of residual BHK cellular DNA was determined by qPCR with a primer-probe set targeting to the Syrian hamster 5S rRNA genomic sequence. The sequences of the a primer-probe set are BHK-F: 5¢-CGCAG CAGCAGGCTCT-3¢; BHK-R: 5¢-ACCCTGCTTAGCTTCCGAGA-3¢; and BHK probe: 5¢-6FAM CCGCCGTCGTCTACGGCCATACC-3¢. Purified BHK genomic DNA was used as standard and the amplification parameters were 2 min at 50 1C, 10 min at 95 1C, followed by 40 cycles of 95 1C for 15 s and 60 1C for 1 min, using an iCycler iQ multi-color sequence detection system (Bio-Rad, Hercules, CA, USA).
The concentration of residual HSV DNA in crude in-process rAAV virus stock or in total DNA extracted from in-process samples was quantified by HSV DNA UL36 qPCR using a plasmid reference standard that contains a single copy of HSV UL36 sequence. 11 Calculation of the HSV DNA concentration (ng ml -1 ) is based on the HSV DNA sequence copy numbers obtained by qPCR, assuming that the HSV DNA fragments are randomly packaged, and each copy of unique HSV UL36 sequence quantified by qPCR represents one copy of whole HSV genome that is 152 kb with an approximate molecular weight of 1.0Â10 8 Da. The limit of quantification of the HSV UL36 qPCR assay is 2.6Â10 4 copies ml -1 , which corresponds to 4.3Â10 À3 ng ml -1 of HSV DNA.
To further determine whether the residual HSV DNA in final purified rAAV preparations was DNase-resistant, purified rAAV with or without spike-in HSV DNA was treated with DNase I (final concentration 100 U ml -1 ) at 37 1C for 1 h, and DNase I was then inactivated by adding 0.5 M EDTA, pH 8.0 to a final concentration of 50 mM and incubating at 70 1C for 20 min. Treated samples were then assayed for HSV DNA by the HSV UL36 qPCR assay. HSV DNA quantification using qPCR targeted to other HSV gene sequences was performed using the same procedure as that for UL36 qPCR assay. The targeted HSV gene sequences include UL26.5, UL28, UL33, and UL35, and the sequences of each primer-probe set for these four HSV DNA qPCR assays were:
UL26.5 forward primer 5¢-CATGTCCTTCCACCCAGAC-3¢; UL26.5 reverse primer 5¢-CCCATCATCTGAGAGACGAA-3¢; UL26.5 probe 5¢-6FAM-CAGC ACACGTGGACGTTGACAC-3¢. UL29 forward primer 5¢-CCGCCTATGGT TACCTTGTC-3¢; UL29 reverse primer 5¢-CCCTCCTGTATCTGGTCGTT-3¢; UL29 probe 5¢-6FAM-AGCCTCCCAGGTGCAGAAAGGT-3¢. UL33 forward primer 5¢-CGAACTTTACGGGACACAATC-3¢; UL33 reverse primer 5¢-C GTAGTCGGGAAGACAACCT-3¢; UL33 probe 5¢-6FAM-TAGACGCGCGC-TACGTCTCG-3¢. UL35 forward primer 5¢-ACGCAAACAACACGTTTACC-3¢; UL35 reverse primer 5¢-TCGAAGGTTCTCGAACGAC-3¢; UL35 probe 5¢-6FAM-CGGCGCACCTATTCACCGTTT-3¢.
Southern blot analysis
DNA extracted from crude, in-process samples, or purified rAAV preparations was subjected to agarose gel electrophoresis and Southern blot analysis. DNA extracted from rAAV1-CB-hAAT made by plasmid transient transfection was used as a negative control. The wtHSV KOS viral DNA digested with AluI was used as a positive control and as the internal control for determining the limit of detection of the assay. Plasmid pCB-AT0 (200 ng), which contains the hAAT expression cassette flanked by AAV2 ITRs, was digested with PciI/PvuI (New England Biolabs, Ipswich, MA, USA) and included as a control for possible non-specific hybridization of the HSV DNA probe to AAV2 ITR or GC-rich CBA promoter sequences. Separation of dsDNA into ssDNA was performed by heat denaturing at 95 1C for 10 min, flash freezing on dry ice, thawing on ice, and loading immediately.
After photography of agarose gels, DNA was transferred to a Biodyne B membrane (Pall, Port Washington, NY, USA) in alkaline conditions with a Turboblot device (Invitrogen, Carlsbad, CA, USA) for 3 h. The membrane was rinsed in 2ÂSSC twice and then hybridized to 32 P-labeled HSV DNA probes in Church hybridization buffer (0.5 M sodium phosphate buffer, pH 7.2, 7% SDS, 1 nM EDTA) at 62 1C for 18 h. Two large HSV DNA fragments excised from cosmids CS32 and C2 were 32 P-labeled with a Random Primed DNA Labeling kit (Roche Molecular Biochemicals, Indianapolis, IN, USA), followed by purification over a ProbeQuant G-50 micro-column (GE Healthcare, Piscataway, NJ, USA) according to the manufacturer's instructions. 13 After hybridization, the blot was briefly rinsed once with 2ÂSSC buffer and then washed four times with 0.1Â SSC, 0.1% (w/v) SDS buffer, 62 1C, 15 min each. The blot was then covered with Saran wrap and exposed to Kodak Biomax MR film (Kodak, Rochester, NY, USA) at À80 1C for 2 days before development.
Silver stain and western blot analysis
In-process samples or final purified rAAV preparations were resuspended in 4X LDS loading buffer and subjected to electrophoresis on NuPAGE Novex 4-12% Bis-tris denaturing polyacrylamide gels (in duplicate) (Invitrogen) according to the manufacturer's instruction. After electrophoresis, one gel was silver stained using the SilverXpress Silver Staining kit (Invitrogen) for total proteins, and the other was subjected to transfer to a PVDF membrane, reacted with an anti-HSV polyclonal antibody (DAKO, Glostrup, Denmark), and detected with ECL Plus Western Blotting Detection Reagents (GE Healthcare) for residual HSV proteins.
Immunofluorescence assay
Approximately 1Â10 5 Vero cells per chamber seeded in eight-chamber tissue culture glass slides (BD Falcon, Bedford, MA, USA) were mock infected or infected with rAAV1-CB-hAAT Lot 11.3.08 (1Â10 10 vg per chamber), or HSV KOS (20 PFU per chamber) in the background of rAAV1-CB-hAAT Lot 11.3.08 (1Â10 10 vg per chamber), or HSV KOS only (20 PFU per chamber). After 48 h, cells were fixed with methanol (À20 1C) for 20 min and then incubated in blocking solution (PBS containing 1% bovine serum albumin and 0.1% saponin) for 1 h at room temperature. Cells were rinsed once with PBS and then reacted at 4 1C with the primary antibodies indicated in the legend of Figure 4 diluted in blocking solution. The polyclonal rabbit antibody to human AAT (Sigma, St Louis, MO, USA) was used at a 1:500 dilution. The mouse monoclonal antibodies to HSV ICP0, ICP8, and ICP35 (Virusys, Sykesville, MD, USA) were used at a 1:250 dilution. After overnight incubation with the primary antibodies, cells were rinsed four times with wash buffer (PBS containing 0.05% Tween 20) and then incubated for 1 h with FITC-conjugated anti-mouse or Texas Red-conjugated anti-rabbit immunoglobulin G (Sigma) at a 1:2000 dilution in blocking solution, rinsed four times with wash buffer, and mounted with Vectashield mounting medium (Vector Lab, Inc., Burlingama, CA, USA). The slides were examined with a fluorescence microscope equipped with a digital camera.
In vitro transcriptional profiling of residual HSV DNA HEK 293 cells were seeded at a density of 6Â10 6 cells per flask in T75 flasks. The next day, cells were mock infected, infected with HSV-1 KOS at a multiplicity of infection of 0.01 PFU per cell, or infected with rAAV1-CBhAAT Lot 11.3.08 at a multiplicity of infection of 1000, 10 000, or 100 000 vg per cell. Cells were harvested 68 h post-infection and total RNA was extracted using an RNAqueous-4 PCR kit (Applied Biosystems, Austin, TX, USA). Purified total RNA was quantified by spectrophotometry, aliquoted, and stored at -80 1C before analysis.
RT-qPCR analysis of purified total RNA was performed using an iCycler realtime PCR Detection System (Bio-Rad) and Taqman One-Step RT-PCR Mix (Applied Biosystems, Inc., Foster City, CA, USA) (100 ng RNA per reaction, in quadruplicate). The five primer-probe sets described above were used to quantify transcripts from HSV UL26.5, UL29, UL33, UL35, and UL36 genes. A Taqman gene expression assay for serpina1 (Applied Biosystems, Inc.) was used to quantify transcripts of hAAT by RT-qPCR. The limit of quantification for each RT-qPCR (cDNA copies per 100 ng of total RNA) was 200 copies for UL33, UL29, UL26.5, and UL35, 20 copies for UL36, and 400 copies for hAAT.
CsCl density gradient fractionation
Purified rAAV1-CB-hAAT Lot 3.12.09 (2Â10 13 vg total) was supplemented with CsCl to a final density of 1.38 g cm -3 and loaded into a Beckman ultracentrifuge tube and subjected to ultracentrifugation at 32 000 r.p.m., 24 h in a SW41 rotor. Fractions of 0.3 ml each were collected from the bottom of the tube with the aid of a Dynamax peristaltic pump (Rainin, Oakland, CA, USA). All fractions were measured for density and rAAV vector concentration, and every second fraction was analyzed for AAV1 capsid using an AAV1 Titration ELISA kit (American Research Products, Inc., Belmont, MA, USA) and HSV DNA by qPCR, as previously described. 11 
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